Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk by Ząbczyk, Michał et al.
1
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11433  | https://doi.org/10.1038/s41598-020-68375-7
www.nature.com/scientificreports
Prothrombotic fibrin clot properties 
associated with NETs formation 
characterize acute pulmonary 
embolism patients with higher 
mortality risk
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Venous thromboembolism is associated with formation of denser fibrin clots resistant to lysis. We 
investigated whether prothrombotic plasma clot properties are associated with the severity of acute 
pulmonary embolism (PE). We enrolled 126 normotensive acute PE patients (aged 58 ± 14 years) and 
25 age‑ and sex‑matched healthy controls. Plasma fibrin clot permeability  (Ks), clot lysis time (CLT), 
endogenous thrombin potential (ETP), plasminogen activator inhibitor‑1 (PAI‑1), and citrullinated 
histone H3 (citH3) were evaluated on admission. PE patients compared to controls had 370% higher 
citH3 levels, 41% higher ETP, 16.5% reduced  Ks, and 25.6% prolonged CLT. Patients with intermediate‑
high (n = 29) and intermediate‑low (n = 77) PE mortality risk had reduced  Ks and prolonged CLT, 
increased PAI‑1 and ETP as compared to low‑risk PE (n = 20) patients. Prolonged CLT was predicted 
by PAI‑1 and citH3, while low  Ks by C‑reactive protein. During a 12‑month follow‑up 9 (7.1%) patients 
who had 24% higher ETP, 45% higher citH3 levels, and 18% prolonged CLT at baseline died. High 
ETP combined with elevated citH3 levels and prolonged CLT was associated with eightfold increased 
risk of PE‑related death. Prothrombotic fibrin clot properties and enhanced neutrophil extracellular 
traps formation are associated with higher early mortality risk in acute PE patients, which suggests a 
prognostic role of these biomarkers.
Acute pulmonary embolism (PE), isolated and combined with deep-vein thrombosis (DVT), remains a major 
cause of mortality, morbidity, and hospitalization related to venous thromboembolism (VTE)1. PE occurs when 
a blood clot, mostly originating from proximal veins of the lower extremities, breaks free and flows to the pul-
monary arteries blocking the blood  flow2. PE is associated with 30-day all-cause mortality rate about 10% and 
three-month mortality up to 17%3. Clinical prediction scores have been developed to standardize diagnosis and 
assess prognosis in acute  PE3. Intermediate-risk PE is associated with mortality ranging from 3 to 14%, while 
high-risk PE up to 24%4. The pathogenesis of PE is multifactorial involving episodes provoked by cancer, surgery, 
hospitalization, estrogen use, along with unprovoked events in > 50% of acute PE  patients3,4. Recently, VTE has 
been linked to the release of neutrophil extracellular traps (NETs)5. Extracellular chromatin and citrullinated 
histones H3 (citH3) have been observed in deep-vein thrombi in  mice6 and VTE  patients7. NETs formation mark-
ers were signifi antly elevated in symptomatic VTE patients compared to healthy  controls5, but NETs formation 
has not been explored in patients with acute PE so far.
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Growing evidence indicates that a prothrombotic clot phenotype, characterized by the formation of compact 
fibrin clots relatively resistant to lysis, can be detected in patients with arterial and venous thromboembolic 
 events8,9, including those following  PE10,11. Faster fibrin degradation has been shown in vitro in patients following 
central versus peripheral  PE12. It has been reported that prothrombotic clot properties may predispose to recur-
rent PE in patients after the fi st-ever PE  episode13. Data about fibrin clot properties in patients with acute PE are 
limited. Martinez et al.14 have shown faster clot lysis time and earlier establishment of clot viscoelastic properties 
among 40 acute PE patients as compared to 35 patients with DVT alone. It is unknown whether fibrin clot prop-
erties assessed on admission in patients with acute PE can refl ct a disease severity and may have a prognostic 
value. Therefore, we investigated plasma clot properties in acute PE and their association with the severity of PE.
Material and methods
Patients. A total of 187 consecutive adult white patients with acute symptomatic PE were recruited from 
December 2016 to March 2019, all emergency admissions, together with concurrently enrolled 25 age- and 
sex-matched healthy controls. The diagnosis of PE was based on the presence of typical symptoms and positive 
results of high resolution spiral computed tomography (CT). Based on the prespecifi d criteria, we excluded 61 
subjects, due to known cancer (n = 12), pregnancy/postpartum (n = 11), high-risk PE with shock or hypotension 
(n = 6), ischemic stroke in the past 3 months (n = 5), myocardial infarction in the past 3 months (n = 2), end-stage 
kidney disease (n = 2), vitamin K antagonist use (n = 2), and 21 due to anti-Xa activity ≥ 0.2 U/mL (arbitrarily 
chosen as a cut-off value based on our previous study)15, because patients who received thromboprophylaxis 
with low-molecular-weight heparins within 12 h were eligible since the diagnosis of PE indicated either non-
compliance or ineffective management.
We assessed the simplifi d PE severity index (sPESI)3. Low-risk PE was indicated by the sPESI of 0. Normo-
tensive PE patients with sPESI of ≥ 1 represented an intermediate-risk group. Using the ESC approach, patients 
with both right ventricular (RV) dysfunction (by echocardiography or CT angiography) and elevated cardiac 
troponin T (TnT) represented an intermediate-high-risk category, while those with normal RV or TnT levels 
were classifi d as an intermediate-low-risk group. RV dysfunction was defi ed as previously  described16. For 
defin tion of DVT, unprovoked VTE, heart failure (HF), and chronic obstructive pulmonary disease (COPD) 
see the Supplementary Material. All participants were contacted at least twice a year through clinic visits after 
3 and 12 months. The primary composite endpoint was the occurrence of recurrent PE and/or DVT or death. 
The Jagiellonian University Ethical Committee approved the study, and participants provided informed written 
consent. All methods were carried out in accordance with relevant guidelines and regulations.
Laboratory investigations. Before initiation of anticoagulant therapy on admission, blood samples were 
drawn from an antecubital vein with minimal stasis. Blood cell count, creatinine, prothrombin time (interna-
tional normalized ratio, INR), activated partial thromboplastin time (aPTT), lipid profile, d-dimer, N-terminal 
B-type natriuretic propeptide (NT-proBNP), and high-sensitivity TnT were assayed by routine laboratory tech-
niques in the hospital laboratory. Positive high-sensitivity TnT was defi ed as a value ≥ 14 pg/mL and positive 
NT-proBNP as a value ≥ 600 pg/mL3. A chromogenic assay was used to measure anti-Xa activity (BIOPHEN, 
Hyphen-Biomed, Neuville-Sur-Oise, France). Fibrinogen was determined using the Clauss method. C-reactive 
protein (CRP) was measured by immunoturbidimetry (Roche Diagnostics, Mannheim, Germany). Plasminogen 
activator inhibitor-1 (PAI-1) and citH3 levels were evaluated using chromogenic or ELISA tests (see Supplemen-
tary Material).
For fibrin clot analyses, blood samples (vol/vol, 9:1 of 3.2% trisodium citrate) were spun at 2500 g for 10 min 
and the supernatant was aliquoted and stored at − 80 °C11,15. All measurements were performed by technicians 
blinded to the origin of the  samples11,15. Intra-assay and inter-assay coeffici ts of variation were 5–7%13. Fibrin 
clot permeation was determined using a pressure-driven  system11. After  Ks measurement, clots were analysed 
using scanning electron microscopy (SEM)13. To assess effici cy of clot lysis, clot lysis time (CLT) was measured 
using the assay of Pieters et al.17. Endogenous thrombin potential (ETP) was performed using calibrated auto-
mated thrombography (Thrombinoscope BV, Maastricht, the Netherlands). For details see the Supplementary 
Material.
Statistical analysis. Variables are presented as numbers and percentages, mean ± standard deviation (SD) 
or median and interquartile range (IQR), as  appropriate15. Normality was assessed by Shapiro–Wilk  test15. 
Equality of variances was assessed using the Levene’s test. Differences between groups were compared using the 
Student’s or the Welch’s t-test depending on the equality of variances for normally distributed  variables15. The 
Mann–Whitney U test was used for non-normally distributed  variables15. Categorical variables were compared 
by the Pearson’s chi-squared test or Fisher’s exact  test15. Multiple group comparisons were performed using 
analysis of variance (ANOVA) or Kruskal–Wallis test. Tukey–Kramer HSD test or Steel–Dwass method was 
used for the post-hoc comparisons. For multiple comparisons of categorical parameters the Benjamini–Hoch-
berg procedure was used. Univariate and multivariate logistic regression models were performed to identify 
independent predictors of prolonged CLT or reduced  Ks (see the Supplementary Material). The best cut-off value 
that maximizes sensitivity and specific ty and differentiates PE patients who died from survivors was calculated 
by using the Receiver Operating Characteristics (ROC) curve. The study was powered to have a 90% chance 
of detecting a 10% difference in fibrin clot characteristics using a p-value of 0.0513. All statistical analyses were 
performed with JMP, Version 13.1.0 (SAS Institute INC., Cary, NC, USA).
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Results
Patient characteristics compared to age- and sex-matched healthy controls are presented in Table S1. Median 
time from the PE symptoms was 4 days (range 0–22 days). Provoked PE was diagnosed in 45 patients, including 
6 (4.8%) women taking oral contraceptives or hormone replacement therapy. In 42 (33.3%) PE patients positive 
TnT was found, while 47 (37.3%) patients had positive NT-proBNP. RV dysfunction was observed in 46 patients 
(36.5%). Compared to controls, acute PE patients had 370% higher citH3 levels, 41% higher ETP and showed 
prothrombotic fibrin clot phenotype as reflected by 16.5% reduced  Ks and 25.6% prolonged CLT (Table S1).
Mortality risk prediction scores. There were 29 (23%) patients with intermediate-high risk PE, 77 
(61.1%) with intermediate-low risk, and 20 (15.9%) subjects with low-risk PE (Table 1). PE patients at interme-
diate-high or -low vs. low mortality risk did not differ with regard to demographic and clinical variables, except 
higher incidence of HF and COPD, and lower prevalence of prior VTE in subjects with higher mortality risk 
(Table 1). Of laboratory investigations, NT-proBNP, PAI-1, and ETP increased with higher mortality risk score 
(Table 1). Intermediate-high risk PE was associated with 19.2% reduced  Ks and 43.5% prolonged CLT and in 
Table 1.  Characteristics of patients with acute pulmonary embolism (PE) according to low, intermediate-
low, and intermediate-high early mortality risk. ACEI angiotensin-converting enzyme inhibitors, ARB 
angiotensin II receptor blockers, CLT clot lysis time, COPD chronic obstructive pulmonary disease, CRP 
C-reactive protein, ETP endogenous thrombin potential, Ks fibrin clot permeability, NT-proBNP N-terminal 
B-type natriuretic propeptide, PAI-1 plasminogen activator inhibitor type 1. *p-value < 0.05 for low risk vs. 
intermediate-low risk vs. intermediate-high risk, respectively (post hoc: †low risk vs. intermediate-low risk, 
‡intermediate-low risk vs. intermediate-high risk, and #low risk vs. intermediate-high risk).
Variable
Early mortality risk
Low risk (n = 20) Intermediate-low risk (n = 77) Intermediate-high risk (n = 29)
Age, years 55 ± 12.7 55.6 ± 14.8 67.2 ± 10.7
Men, n (%) 13 (65) 40 (51.9) 13 (44.8)
Body-mass index, kg/m2 28.6 ± 5.2 27.9 ± 4.6 28.5 ± 6
Current smoking, n (%) 4 (20) 14 (18.2) 7 (24.1)
Clinical characteristics, n (%)
Prior venous thromboembolism 3 (15)* 6 (7.8)*† 0*#
Coronary heart disease 7 (35) 33 (42.9) 10 (34.5)
Prior myocardial infarction 1 (5) 19 (24.7) 5 (17.2)
Prior stroke 1 (5) 6 (7.79) 3 (10.3)
Hypertension 9 (45) 38 (49.4) 21 (72.4)
Heart failure 0* 17 (22)*† 8 (27.6)*#
Diabetes mellitus 6 (30) 26 (33.8) 10 (34.5)
COPD 0* 8 (10.4)*† 4 (13.8)*#
Medications, n (%)
Beta blockers 20 (100)* 50 (64.9)*† 21 (72.4)*#
ACEI 12 (60) 42 (54.5) 20 (69)
ARB 5 (25)* 11 (14.3)* 0*‡#
Calcium channel blockers 1 (5) 11 (14.3) 4 (13.8)
Aspirin 5 (25) 25 (32.5) 10 (34.5)
Statin 13 (65) 46 (59.7) 18 (62.1)
Characteristics of acute PE
PE symptoms, days 3.5 [1.5–7] 4 [2–7] 3 [2–7]
Unprovoked PE, n (%) 10 (55) 52 (67.5) 19 (65.5)
Laboratory investigations
Fibrinogen, g/L 3.08 [2.15–3.60] 3.33 [2.82–3.96] 3.22 [2.78–3.95]
CRP, mg/L 2.25 [1.48–6.24]* 3.62 [1.71–12.37]* 10.15 [2.63–23.34]*#
D-dimer, ng/mL 3,345 [2008–5983] 2,600 [1546–5053] 3,837 [2346–7770]
NT-proBNP, pg/mL 91.5 [59–104.5]* 444 [211–987]*† 1,261 [384–3571]*‡#
PAI-1, ng/mL 16.5 [11.4–23.3]* 22.7 [17.4–30]* 31 [19.8–45.8]*#
Citrullinated histone H3, ng/mL 2.28 [1.87–2.71] 2.92 [1.97–3.87] 3.44 [1.46–4.2]
ETP, nM × min 1508 [1436–1580]* 1683 [1499–1891]*† 1811 [1598–2395]*#
Fibrin clot properties
Ks, × 10-9cm2 7.3 [7.0–7.8]* 6.4 [5.6–7.2]*† 5.9 [4.8–7.0]*#
CLT, min 85 [79.5–90]* 108 [98–119]*† 122 [106–149]*‡#
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patients with intermediate-low mortality risk  Ks was 12.3% lower, while CLT was 27.1% longer as compared to 
those with low risk (Fig. 1A,B). 
sPESI score ≥ 2 was found in 65 (51.6%) patients, sPESI = 1 in 41 (2.5%), while 20 (15.9%) subjects had 
sPESI = 0 (Table S2). Levels of fibrinogen, CRP, NT-proBNP, and PAI-1 increased with sPESI score (Table 2). 
Interestingly, patients with sPESI score ≥ 2 compared to those with sPESI = 0 had 50% higher citH3 levels 
(Table S2). Higher ETP was observed in patients with sPESI ≥ 2 or 1 compared to low-risk patients (Table S2), 
with no intergroup differences in other haemostatic parameters. Subjects with sPESI score ≥ 2 or 1 had 35.3% 
and 16.5% longer CLT compared with low-risk patients with sPESI = 0, respectively (Table S2). Reduced  Ks by 
19.2% was observed in subjects with sPESI ≥ 2 compared to the former group (Table S2).
Associations of fibrin clot properties. We found reduced  Ks in patients with elevated TnT (Fig. 2A) and 
NT-proBNP (Fig. 2B), but not RV dysfunction (Fig. 2C).  Ks was inversely associated with fibrinogen (r = − 0.32, 
p < 0.001), CRP (r = − 0.27, p = 0.0019), NT-proBNP (r = − 0.22, p = 0.012), and d-dimer (r = − 0.19, p = 0.038).
PE patients with positive TnT or NT-proBNP and those with RV dysfunction had prolonged CLT compared 
to the remainder (Fig. 2D–F). We observed linear associations of CLT with NT-proBNP (r = 0.29, p = 0.001) and 
ETP (r = 0.60, p < 0.001). Plasma citH3 concentrations correlated with CLT (Fig. 3) but not with  Ks.
Predictors of clot density and lysability. After adjustment for age, sex, BMI, and fibrinogen levels, the 
independent predictors of CLT > 121.5 min (the top quartile, n = 32) were PAI-1 and citH3 levels (odds ratio 
[OR] = 1.09, 95% confide ce interval [CI] 1.05–1.15 and OR = 1.80, 95% CI 1.26–2.70 per 1 unit increase, respec-
tively), while  Ks ≤ 5.46 × 10–9cm2 (the fi st quartile, n = 32) was predicted by CRP (OR = 1.49, 95% CI 1.16–2.10 
per 10 units increase).
Figure 1.  Fibrin clot permeability  (Ks, A) and clot lysis time (CLT, B) determined in acute PE patients with low, 
intermediate-low, and intermediate-high early mortality risk (both p < 0.05 for ANOVA).
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Table 2.  Characteristics of acute PE patients with intermediate early mortality risk who died and survivors 
at 1-year follow-up. Data are shown as numbers (%) or median [1st quartile-3rd quartile]. Ks fibrin clot 
permeability, CLT clot lysis time.
Variable PE-related death (n = 9) Survivors (n = 97) P value
Age, years 68 [61–80] 58 [40–70] 0.032
Men, n (%) 4 (44.4) 49 (50.5) 0.73
Body-mass index, kg/m2 26 [23–30] 27 [24–31] 0.28
Characteristics of acute PE
Intermediate-low mortality risk, n (%) 2 (22.2) 75 (89.3)
0.0004
Intermediate-high mortality risk, n (%) 7 (77.8) 22 (26.2)
Right ventricular dysfunction, n (%) 8 (88.9) 38 (39.2) 0.004
Unprovoked PE, n (%) 7 (77.8) 64 (66) 0.47
Clinical characteristics, n (%)
Prior venous thromboembolism, n (%) 0 6 (6.2) 0.58
Coronary heart disease, n (%) 3 (33.3) 40 (41.2) 0.64
Prior myocardial infarction, n (%) 2 (22.2) 22 (22.7) 0.97
Prior stroke, n (%) 1 (11.1) 8 (8.2) 0.77
Hypertension, n (%) 3 (33.3) 56 (57.7) 0.16
Heart failure, n (%) 2 (22.2) 23 (23.7) 0.92
Diabetes mellitus, n (%) 3 (33.3) 33 (34) 0.97
Chronic obstructive pulmonary disease, n (%) 0 12 (12.4) 0.59
Laboratory investigations
Endogenous thrombin potential, nM × min 2088 [1765–2593] 1688 [1499–1943] 0.031
Citrullinated histone H3, ng/mL 4.49 [3.66–5.62] 3.1 [1.9–3.98] 0.038
Ks, × 10-9cm2 5.60 [4.90–5.91] 6.35 [5.45–7.2] 0.066
CLT, min 129 [115–149] 109 [99–124] 0.029
Figure 2.  Fibrin clot permeability  (Ks) and clot lysis time (CLT) in acute PE patients with positive vs. negative 
TnT (A,D) and NT-proBNP (B,E) and with or without right ventricular (RV) dysfunction (C,F).
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Clot imaging. SEM analysis performed in 28 clots prepared from plasma of healthy controls and patients 
with low, intermediate-low and intermediate-high early mortality risk (each, n = 7) revealed a smaller fibrin fibre 
diameter in PE patients compared to controls, especially in those with higher mortality risk (Fig. 4) in relation 
to lower  Ks. The corresponding median fibre diameter was 156 [149–174] nm, 141 [138–145] nm, 134 [130–136] 
nm, and 121 [119–126] nm, respectively (p < 0.01 for ANOVA).
Mortality among PE patients. All patients were on anticoagulation, mostly on rivaroxaban 20 mg/day. 
Two patients who died stopped anticoagulation with rivaroxaban due to trauma or invasive procedure prior to 
fatal PE. Five acute PE patients (3.97%) died within 30 days since admission, while four (3.2%) subjects died 
during a 1-year follow-up. Patients who died after acute PE event (n = 9, 7.14%) compared to survivors were 
older, more often had RV dysfunction, and were characterized by 24% higher ETP, 45% increased citH3 lev-
els, and 18% prolonged CLT on admission (Table 2). A tendency to reduced  Ks was also observed (p = 0.066; 
Table 2). Cut-off values which discriminated intermediate-risk PE patients who died from survivors were for 
ETP above 1707 ng/ml (sensitivity, 100% and specific ty, 52%, area under curve [AUC] 0.779, 95% CI 0.653–
0.905, p < 0.0001; Fig. 5A), for citH3 above 4.11 ng/ml (sensitivity, 67% and specific ty, 83%, AUC 0.771, 95% CI 
0.611–0.930, p = 0.0009; Fig. 5B), and for CLT above 111 min (sensitivity, 100% and specific ty, 54%; AUC 0.782, 
95% CI 0.662–0.901, p < 0.0001; Fig. 5C). Individuals with high ETP combined with elevated citH3 levels and 
prolonged CLT based on optimal cut-off values estimated using ROC analysis had the highest risk of PE-related 
death (OR, 9.3; 95% CI 2.1–40.3).
Discussion
Th s study is the fi st to show that prothrombotic plasma fibrin clot properties accompanied by enhanced throm-
bin generation potential, increased PAI-1 concentrations, and interestingly enhanced NETs formation, character-
ize patients with more severe acute PE. Our novel fi ding is that prolonged CLT assessed in plasma on admission 
might help identify intermediate-risk patients with acute PE at increased risk of PE-related death. Effici cy 
of fibrinolysis using various plasma-based assays, including the most commonly used CLT, has been studied 
in patients with a history of acute thromboembolic  event8,10. Its prognostic value has been reported in terms of 
recurrent  thromboembolism13,15,18,19 and adverse outcomes following acute coronary  syndrome9. The present 
study provides novel fi dings suggesting that measurement of CLT in acute PE might offer valuable information 
on short-term prognosis.
Denser fibrin networks observed in subjects with intermediate PE risk compared to those with low PE risk 
is a novel finding and deserves a comment. In our cohort of acute PE patients CRP predicted reduced  Ks. CRP 
has been reported to bind to fibrinogen and modify fibrin  formation8,20. It might suggest that the architecture of 
plasma fibrin clots formed in vitro in acute PE is associated with the disease severity, indicating the mechanism 
which is driven by the inflammation, at least in part by NETs formation. Of note, recently it has been shown that 
fibrin structure may contribute to long-term complications after acute  PE21. Both  Ks and CLT were associated 
with positive TnT and NT-proBNP, biomarkers related to the cardiac injury, cardiac stress, and RV dysfunction in 
acute  PE3,22. Levels of NT-proBNP have been shown to predict the 30-day adverse outcome in acute PE  patients23. 
Of note, the 2019 ESC Guidelines for the diagnosis and management of acute PE downplayed the role of NT-
proBNP in PE mortality risk  estimation3, however, it is still considered as an additional prognostic biomarker. 
Our study showed that NT-proBNP could be a valuable marker of the prothrombotic and hypofibrinolytic state 
driven by increased thrombin generation and inflammation, similarly to patients with atrial  fibrillation24–26. It is 
likely that the secondary prothrombotic effects associated with common consequences of acute clinical setting as 
enhanced inflammatory state or hemodynamic abnormalities are superimposed on the primary clot phenotype, 
which is determined by congenital and environmental factors present prior to acute  PE27. Th s issue requires 
however further investigations.
Figure 3.  Association of clot lysis time with citrullinated histone H3 (citH3) levels in acute PE patients.
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We confi med our hypothesis on the impact of NETs formation on acute PE, because in the present study, 
increased NETs formation, refl cted by citH3 levels, was positively associated with impaired fibrinolysis. Our 
data suggests that NETs formation contributes to slower fibrinolysis a few days since the acute PE symptom 
onset. As shown by Longstaff et al.28, clots rich in DNA and histones are resistant to fibrinolysis. The relevance 
of NETosis in acute PE underscores our observation that elevated circulating citH3 in acute PE might be linked 
to disease severity by enhancing the inflammatory and prothrombotic state. Further large-scale studies on the 
role of NETs formation in acute VTE and its prognostic value should be conducted.
Our study has several limitations. First, the number of study participants was limited, however, the study 
was adequately powered to detect intergroup differences in clot properties. Second, high-risk PE patients and 
cancer patients were excluded, therefore our fi dings could not be extrapolated to these subsets. Cancer and 
pregnancy are potent prothrombotic factors negatively altering clot  phenotype29. We decided to enrol women 
with contraceptives-related PE because it is not clear whether this type of PE differs from other types. Third, 
we evaluated fibrin clot properties using platelet-poor plasma, therefore the impact of platelets and blood cells 
cannot be assessed using this approach. Finally, due to limited number of patients the influence of different 
comorbidities on fibrin clot properties impairment in acute PE patients was difficult to assess.
In conclusion, prothrombotic fibrin clot properties in acute PE driven at least in part by enhanced NETs 
formation are associated with the PE severity. Th s suggests that a subgroup of normotensive noncancer PE 
Figure 4.  Representative scanning electron micrographs showing morphology of fibrin clots prepared from 
plasma of healthy control and acute PE patients with similar fibrinogen levels. Scale bar 5 or 2 µm.
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Figure 5.  ROC curves for endogenous thrombin potential (A), citrullinated histone H3 (B), and clot lysis time 
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patients with more compact clot structure and impaired fibrinolysis detected on admission should be under 
close clinical surveillance after discharge within the fi st year. Further studies on large cohorts of PE patients are 
needed to confi m our findings.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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